Juventas Cell Therapy Ltd. (China)
A Chinese biopharmaceutical company focused on cell therapy, founded in June 2018.
Last updated September 1, 2026
Overview
Juventas Cell Therapy Ltd. (China) is a biopharmaceutical company founded in June 2018, dedicated to becoming a global leader in cell and gene innovative technology-driven next-generation biopharmaceutical enterprise. Its first core product, Yuanruida (Inaticabtagene Autoleucel Injection, CNCT19), was approved for marketing by the National Medical Products Administration in November 2023, making it the first CAR-T drug in the field of leukemia treatment in China and the first fully self-innovated CD19 CAR-T drug in China.
History
Juventas Cell Therapy Ltd. (China) was founded in June 2018. In June 2021, it obtained the first cell drug 'Drug Production License' in Tianjin. In November 2023, its first core product Yuanruida (Inaticabtagene Autoleucel Injection, CNCT19) was officially approved for marketing by the National Medical Products Administration (NMPA).
Sources
Cite this profile: Cite the canonical profile. /brand-wiki/juventas-cell-therapy-ltd-china · Editorial policy · How profiles are compiled